Focused on developing innovative therapeutics through a decentralized model, this biopharmaceutical company leverages subsidiary 'Vants' to accelerate drug development across multiple disease areas. Investors monitor its pipeline progress and partnerships with major pharma firms given its unique approach to reducing R&D inefficiencies.
1 member of Congress has disclosed 4 trades in Roivant Sciences Ltd. (ROIV), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 2 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-10-31 | Lisa McClain | sell | $1K – $15K |
| 2025-10-30 | Lisa McClain | sell | $1K – $15K |
| 2025-10-30 | Lisa McClain | buy | $1K – $15K |
| 2025-06-17 | Lisa McClain | buy | $1K – $15K |